How to buy Medicago stock as its vaccine shows 71% efficacy?

2 min read | December 07, 2021 08:58 AM EST | By Raza Naqvi

Highlights 

  • Medicago and GlaxoSmithKline’s vaccine has demonstrated 71 per cent efficacy against multiple variants of the coronavirus.
  • The study was conducted on 24,000 people and no vaccinated participants developed serious side effects or severe disease.
  • Potential investors are looking for the Medicago stock in Canada as its vaccine has shown effectiveness against multiple variants.

Canadian drugmaker Medicago announced on Tuesday, December 7, that its plant-based vaccine for coronavirus has shown effectiveness against the virus.

The vaccine was made in collaboration with GlaxoSmithKline Plc (NYSE:GSK) and it has demonstrated 71 per cent efficacy against multiple variants of the coronavirus.

In addition, the vaccine makers observed that their vaccine showed 75 per cent efficacy against the Delta variant and 89 per cent against the gamma variant, which was first identified in Brazil.

How to buy Medicago stock as its vaccine shows 71% efficacy

The study was conducted on 24,000 people and no vaccinated participants developed serious side effects or severe disease. After the announcement, investors are searching for the Medicago stock as the vaccine efficacy is a big development.

Can you buy the Medicago stock?

You cannot buy the Medicago stock in Canada as it does not trade on the Toronto Stock Exchange (TSX). In 2013, the shares of the company were delisted from the TSX as Tokyo-based Mitsubishi Chemical Holdings bought Medicago for $357 million.

© 2021 Kalkine Media®
Image Description: Medicago stock

If investors want to invest in Medicago, then there's an alternate option of investing in Mitsubishi Chemical. However, the stock of this company is available on the Tokyo Stock Exchange and trades under the stock symbol 4188.

Also Read: 3 Canadian COVID stocks to buy amid Omicron’s emergence

Interested investors will have to find a trading account of a brokerage company that deals in international stocks. The 4188 stock jumped 1.3 per cent during the trading session on December 7 and closed at 858 JPY.

Meanwhile, the New York Stock Exchange-listed GSK stock has climbed around one per cent during pre-market hours.

Bottom line

The study results did not include the recently identified omicron variant and Medicago is planning to test the vaccine against the strain.

Also Read: 7 Canadian stocks to buy at discount amid Omicron selloff

Both the companies have begun the process to seek approval from the regulatory authorities in the US, Canada, the United Kingdom, and other countries.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.